VF
GTBP icon

Virtu Financial’s GT Biopharma GTBP Stock Holding History

Virtu Financial’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-595
Closed -$6K – 1860
2026
Q1 		$6K Buy
+595
New +$8.12K ﹤0.01% 1493
2022
Q4 		– Sell
-33
Closed -$44K – 1831
2022
Q3 		$44K Buy
+33
New +$63.1K ﹤0.01% 1231
2021
Q2 		– Sell
-30
Closed -$156K – 1725
2021
Q1 		$156K Buy
+30
New +$131K 0.01% 1179

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HRT Financial
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
Arax Advisory Partners
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $479M AUM 15.43% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Virtu Financial's GTBP Position: Q2 2026 in Review

Virtu Financial sold out of GT Biopharma (GTBP) in Q2 2026, closing a stake of 595 shares — an estimated $6K sold.

Virtu Financial first reported a position in GTBP in Q1 2021 and held it in 3 quarters. The position peaked at $156K in Q1 2021. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Virtu Financial reported no remaining GT Biopharma position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 595 GT Biopharma shares in Q2 2026, an estimated $6K.
  • Virtu Financial first reported a position in GT Biopharma in Q1 2021 and held it in 3 quarters.
  • Virtu Financial's GT Biopharma position peaked at $156K in Q1 2021.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.